The Impact of COVID-19 on Patients With ADPKD

Purpose of review: Patients with autosomal dominant polycystic kidney disease (ADPKD) have kidney cysts and kidney enlargement decades before progressing to advanced chronic kidney disease (CKD), meaning patients live most of their adult life with a chronic medical condition. The coronavirus disease...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Meherzad Kutky, Erin Cross, Darin J. Treleaven, Ahsan Alam, Matthew B. Lanktree
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/73628a7e14dd4b9b868691f5669d5036
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:73628a7e14dd4b9b868691f5669d5036
record_format	dspace
spelling	oai:doaj.org-article:73628a7e14dd4b9b868691f5669d50362021-11-10T23:03:35ZThe Impact of COVID-19 on Patients With ADPKD2054-358110.1177/20543581211056479https://doaj.org/article/73628a7e14dd4b9b868691f5669d50362021-11-01T00:00:00Zhttps://doi.org/10.1177/20543581211056479https://doaj.org/toc/2054-3581Purpose of review: Patients with autosomal dominant polycystic kidney disease (ADPKD) have kidney cysts and kidney enlargement decades before progressing to advanced chronic kidney disease (CKD), meaning patients live most of their adult life with a chronic medical condition. The coronavirus disease 2019 (COVID-19) pandemic has created common questions among patients with ADPKD. In this review, we discuss COVID-19 concerns centered around a patient with a common clinical vignette. Sources of information: We performed PubMed and Google scholar searches for English, peer-reviewed studies related to “COVID-19,” “ADPKD,” “CKD,” “tolvaptan,” “angiotensin-converting enzyme inhibitors” (ACEi), “angiotensin receptor blockers” (ARB), and “vaccination.” We also evaluated transplant data provided by the Ontario Trillium Gift of Life Network. Methods: Following an assessment of available literature, this narrative review addresses common questions of patients with ADPKD in the context of the COVID-19 pandemic. Key findings: Data regarding the risk of developing COVID-19 and the risk of adverse COVID-19 outcomes in patients with ADPKD remain limited, but patients with ADPKD with impaired estimated glomerular filtration rate (eGFR), kidney transplants, or on dialysis are likely at similar increased risk as those with generally defined CKD. We provide strategies to improve virtual care, which is likely to persist after the pandemic. Current evidence suggests ACEi, ARB, and tolvaptan treatment should be continued unless contraindicated due to severe illness. When available, and in the absence of a severe allergy, vaccination is recommended for all patients with ADPKD. Limitations: This narrative review is limited by a paucity of high-quality data on COVID-19 outcomes in patients specifically with ADPKD. Implications: Patients with ADPKD who have developed advanced CKD, require dialysis, or who have received a kidney transplant are at elevated risk of COVID-19 complications.Meherzad KutkyErin CrossDarin J. TreleavenAhsan AlamMatthew B. LanktreeSAGE PublishingarticleDiseases of the genitourinary system. UrologyRC870-923ENCanadian Journal of Kidney Health and Disease, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the genitourinary system. Urology RC870-923
spellingShingle	Diseases of the genitourinary system. Urology RC870-923 Meherzad Kutky Erin Cross Darin J. Treleaven Ahsan Alam Matthew B. Lanktree The Impact of COVID-19 on Patients With ADPKD
description	Purpose of review: Patients with autosomal dominant polycystic kidney disease (ADPKD) have kidney cysts and kidney enlargement decades before progressing to advanced chronic kidney disease (CKD), meaning patients live most of their adult life with a chronic medical condition. The coronavirus disease 2019 (COVID-19) pandemic has created common questions among patients with ADPKD. In this review, we discuss COVID-19 concerns centered around a patient with a common clinical vignette. Sources of information: We performed PubMed and Google scholar searches for English, peer-reviewed studies related to “COVID-19,” “ADPKD,” “CKD,” “tolvaptan,” “angiotensin-converting enzyme inhibitors” (ACEi), “angiotensin receptor blockers” (ARB), and “vaccination.” We also evaluated transplant data provided by the Ontario Trillium Gift of Life Network. Methods: Following an assessment of available literature, this narrative review addresses common questions of patients with ADPKD in the context of the COVID-19 pandemic. Key findings: Data regarding the risk of developing COVID-19 and the risk of adverse COVID-19 outcomes in patients with ADPKD remain limited, but patients with ADPKD with impaired estimated glomerular filtration rate (eGFR), kidney transplants, or on dialysis are likely at similar increased risk as those with generally defined CKD. We provide strategies to improve virtual care, which is likely to persist after the pandemic. Current evidence suggests ACEi, ARB, and tolvaptan treatment should be continued unless contraindicated due to severe illness. When available, and in the absence of a severe allergy, vaccination is recommended for all patients with ADPKD. Limitations: This narrative review is limited by a paucity of high-quality data on COVID-19 outcomes in patients specifically with ADPKD. Implications: Patients with ADPKD who have developed advanced CKD, require dialysis, or who have received a kidney transplant are at elevated risk of COVID-19 complications.
format	article
author	Meherzad Kutky Erin Cross Darin J. Treleaven Ahsan Alam Matthew B. Lanktree
author_facet	Meherzad Kutky Erin Cross Darin J. Treleaven Ahsan Alam Matthew B. Lanktree
author_sort	Meherzad Kutky
title	The Impact of COVID-19 on Patients With ADPKD
title_short	The Impact of COVID-19 on Patients With ADPKD
title_full	The Impact of COVID-19 on Patients With ADPKD
title_fullStr	The Impact of COVID-19 on Patients With ADPKD
title_full_unstemmed	The Impact of COVID-19 on Patients With ADPKD
title_sort	impact of covid-19 on patients with adpkd
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/73628a7e14dd4b9b868691f5669d5036
work_keys_str_mv	AT meherzadkutky theimpactofcovid19onpatientswithadpkd AT erincross theimpactofcovid19onpatientswithadpkd AT darinjtreleaven theimpactofcovid19onpatientswithadpkd AT ahsanalam theimpactofcovid19onpatientswithadpkd AT matthewblanktree theimpactofcovid19onpatientswithadpkd AT meherzadkutky impactofcovid19onpatientswithadpkd AT erincross impactofcovid19onpatientswithadpkd AT darinjtreleaven impactofcovid19onpatientswithadpkd AT ahsanalam impactofcovid19onpatientswithadpkd AT matthewblanktree impactofcovid19onpatientswithadpkd
_version_	1718439683538550784

The Impact of COVID-19 on Patients With ADPKD

Ejemplares similares